ArticleFrontiers in cellular and infection microbiology2026
Sustained persistence of blockade antibodies against emerging GII.4 and GII.17 noroviruses revealed by a 5-year community-based serological study.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: GII noroviruses (NoVs) are the leading cause of viral gastroenteritis worldwide. A critical unresolved question is whether natural infection elicits long-lasting protective antibodies, which is paramount for guiding vaccine development. The long-term persistence of functional neutralizing antibodies against the predominant GII genogroup remains poorly characterized. Methods: In a 5-year community-based prospective cohort (2014-2018), we longitudinally assessed seroprevalence, seroincidence, and persistence of blockade antibodies against GII.4, GII.6, and GII.17 NoVs in 449 adults. HBGA (human histo-blood group antigen) associations with susceptibility were also analyzed. Results: GII.4 exhibited the highest and most stable seroprevalence (77.3-79.7%), while GII.17 seroprevalence rose sharply from 41.9% to 72.2%, capturing its emergence as an epidemic strain. Seroincidence was substantial, highest for GII.17 (30.4 per 100 person-years). In contrast to GI NoVs, GII.4 and GII.17 antibody exhibited exceptional persistence, with five-year persistence rate of 94.5% for GII.4 and 81.4% for GII.17, respectively, and no significant decay in blockade activity-both significantly exceeding the 61.2% persistence of GII.6. HBGA susceptibility patterns were distinct: GII.4 and GII.6 were associated with secretor status and Lewis antigens, while only blood type A was linked to GII.17 susceptibility. Conclusion: This study provides the first longitudinal evidence that natural infection with major GII NoVs, particularly GII.4 and the emerging GII.17, elicits robust and sustained functional antibody responses that persist for at least five years. This fundamental genogroup-specific disparity in immune durability, contrasting sharply with transient GI immunity, reveals a new dimension of NoVs immunology and provides a critical evidence base for the design of effective, long-lasting vaccines.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.